Table 1 Patient characteristics.
From: Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
Characteristics | All (n = 199) | Prevalent nonsynonymous BCL2 Mutationa (N = 48) | All other patients (N = 151) | P value |
|---|---|---|---|---|
Age (median, range) | 61 (23–91) | 61 (30–84) | 61 (23–91) | 0.90 |
Gender, male % | 99 (50%) | 30 (63%) | 69 (46%) | 0.043 |
Stage | ||||
1 | 24 (12%) | 3 (6%) | 21 (14%) | 0.36 |
2 | 27 (14%) | 6 (13%) | 21 (14%) | |
3 | 51 (26%) | 11 (23%) | 40 (26%) | |
4 | 97 (49%) | 28 (58%) | 69 (46%) | |
B symptoms (present) | 12(6%) | 4 (8%) | 8 (5%) | 0.46 |
LDH > ULN | 33 (18%) | 8 (19%) | 25 (18%) | 0.96 |
Hemoglobin <12 | 20 (11%) | 7 (16%) | 13 (10%) | 0.27 |
Grade | ||||
1–2 | 175 (88%) | 42 (88%) | 133 (88%) | 0.91 |
3 A | 24 (12%) | 6 (13%) | 18 (12%) | |
FLIPI | ||||
0–1 | 71 (36%) | 10 (21%) | 63 (42%) | 0.032 |
2 | 74 (38%) | 22 (46%) | 50 (33%) | |
3–5 | 51 (26%) | 16 (33%) | 38 (25%) | |
Initial therapy | ||||
Non-systemic | ||||
Observation | 85 (43%) | 11 (23%) | 74 (49%) | 0.0026 |
Radiation only | 12 (6%) | 2 (4%) | 10 (7%) | |
Rituximab containing | ||||
Rituximab | 7 (15%) | 16 (11%) | ||
monotherapy | 23 (12%) | |||
R-CVP | 33 (17%) | 14 19%) | 19 (13%) | |
R-CHOP | 33 (17%) | 8 (17%) | 25 (17%) | |
Radioimmunotherapy | 2 (1%) | 2 (4%) | 0 | |
Otherb | 11 (6%) | 4 (8%) | 7 (5%) | |
